Baird Maintains Outperform on Qiagen, Raises Price Target to $52
Baird analyst Catherine Schulte maintains Qiagen (NYSE:QGEN) with a Outperform and raises the price target from $50 to $52.
Share
Why It Matters
An expert analyst thinks Qiagen is still a good choice to own. The analyst raised their guess of what the stock should be worth.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.